SCHEMBL1779092

SCHEMBL1779092

CCOC(=O)n1nc(NC(=O)c2ccccc2NC(=O)C2CCOCC2)c2cc(C(=O)NC(C)(C)c3ccccc3)sc21

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 7/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ABL1 P00519 2/20 0.36
BCR P11274 2/20 0.36
AURKA O14965 1/20 0.36
PTGER1 P34995 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
CNR1 P21554 2/20 0.35
CNR2 P34972 2/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1779178 0.91 MEN1 (0.38) RXFP1MEN1KMT2APTGER1HDAC3
SCHEMBL1780238 0.90 PTGER1 (0.39) MEN1KMT2APTGER1HDAC3HDAC1
SCHEMBL1779953 0.89 AURKA (0.46) ABL1BCRAURKAMAPT
SCHEMBL1780872 0.89 KMT2A (0.44) RXFP1MEN1KMT2APTGER1HDAC3
SCHEMBL1778509 0.84 RXFP1 (0.41) RXFP1MEN1KMT2ATP53POLB
SCHEMBL1779652 0.84 RXFP1 (0.36) RXFP1MEN1KMT2AABL1BCR
SCHEMBL1778679 0.83 MAPT (0.37) RXFP1ABL1BCRAURKATP53
SCHEMBL1433343 0.82 ABL1 (0.39) RXFP1ABL1BCRAURKATP53
SCHEMBL1779428 0.82 ABL1 (0.40) RXFP1MEN1KMT2AABL1BCR
SCHEMBL1780180 0.82 KDM4E (0.38) MEN1KMT2AABL1BCRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 RXFP1 3180/4885MEN1 4395/4885KMT2A 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.